PAZEO® Solution is Formulated for 24-hour ocular itch relief in one drop1

PAZEO® Solution delivers the highest concentration—0.7%—of olopatadine hydrochloride1-3

Olopatadine Concentration

PAZEO® Solution pH Comparison

A 24-hour ocular allergy itch relief drop with no FDA-approved generic therapeutic equivalent available5

  • A generic drug product is one that is comparable to an innovator drug product in dosage form, strength, route of administration, quality, performance characteristics, and intended use8
  • There is no generic therapeutic equivalent to PAZEO® Solution5

Once-daily dosing

  • The recommended dosage of PAZEO® Solution is to instill one drop in each affected eye once a day1

†Based on Alcon’s prescription eye allergy medications: PATANOL® (olopatadine hydrochloride ophthalmic solution) 0.1%, PATADAY® (olopatadine hydrochloride ophthalmic solution) 0.2%, and PAZEO® Solution.

Learn how to help eligible patients save with the PAZEO® Solution Co-Pay Savings Card*
Review the safety profile of PAZEO® Solution1

INDICATION AND DOSING

PAZEO® Solution is indicated for the treatment of ocular itching associated with allergic conjunctivitis. The recommended dosage is to instill one drop in each affected eye once a day. 

IMPORTANT SAFETY INFORMATION

As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle to prevent contaminating the tip and solution. Keep bottle tightly closed when not in use. 

Patients should not wear a contact lens if their eye is red. PAZEO® Solution should not be used to treat contact lens-related irritation. The preservative in PAZEO® Solution, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least five minutes after instilling PAZEO® Solution before they insert their contact lenses. 

The most commonly reported adverse reactions in a clinical study occurred in 2%-5% of patients treated with either PAZEO® Solution or vehicle. These events were blurred vision, dry eye, superficial punctate keratitis, dysgeusia, and abnormal sensation in eye. 

For additional information on PAZEO® Solution, please click here to view the full Prescribing Information.

*Terms and Conditions:

Limitations apply. For commercially insured patients. Up to a $125 cap per bottle. Patient will be responsible for any co-pay once limit per bottle is reached. This offer is not valid under Medicare, Medicaid, or any other federal or state program. Not valid for cash-paying patients. Novartis reserves the right to rescind, revoke, or amend this program without notice. Offer expires 12/31/2017.

References: 1. PAZEO® [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2016. 2. PATADAY® [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2010. 3. PATANOL® [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2007. 4. Data on file, 2012. 5. US Department of Health and Human Services. Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations. In: The Orange Book. 36th ed. Rockville, MD: US Department of Health and Human Services; 2016. 6. Milder B. The lacrimal apparatus. In: Moses RA, ed. Physiology of the Eye: Clinical Application. 7th ed. St. Louis, MO: The C.V. Mosby Company; 1981:16-37. 7. Yamada M, Mochizuki H, Kawai M, Yoshino M, Mashima Y. Fluorophotometric measurement of pH of human tears in vivo. Curr Eye Res. 1997;16(5):482-486. 8. Food and Drug Administration website. Abbreviated new drug application (ANDA): generics. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics. Updated November 16, 2016. Accessed February 23, 2017. 

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION & DOSING

PAZEO®Solution is indicated for the treatment of ocular itching associated with allergic conjunctivitis. The recommended dosage is to instill one drop in each affected eye once a day. 

IMPORTANT SAFETY INFORMATION

As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle to prevent contaminating the tip and solution. Keep bottle tightly closed when not in use. 

Patients should not wear a contact lens if their eye is red. PAZEO® Solution should not be used to treat contact lens-related irritation. The preservative in PAZEO®Solution, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least five minutes after instilling PAZEO® Solution before they insert their contact lenses. 

The most commonly reported adverse reactions in a clinical study occurred in 2%-5% of patients treated with either PAZEO®Solution or vehicle. These events were blurred vision, dry eye, superficial punctate keratitis, dysgeusia, and abnormal sensation in eye. 

For additional information on PAZEO® Solution, please click here to view the full Prescribing Information.

*Terms and Conditions:

Limitations apply. For commercially insured patients. Up to a $125 cap per bottle. Patient will be responsible for any co-pay once limit per bottle is reached. This offer is not valid under Medicare, Medicaid, or any other federal or state program. Not valid for cash-paying patients. Novartis reserves the right to rescind, revoke, or amend this program without notice. Offer expires 12/31/2017.

References: 1. PAZEO® [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2016. 2. PATADAY® [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2010. 3. PATANOL® [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2007. 4. Data on file, 2012. 5. US Department of Health and Human Services. Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations. In: The Orange Book. 36th ed. Rockville, MD: US Department of Health and Human Services; 2016. 6. Milder B. The lacrimal apparatus. In: Moses RA, ed. Physiology of the Eye: Clinical Application. 7th ed. St. Louis, MO: The C.V. Mosby Company; 1981:16-37. 7. Yamada M, Mochizuki H, Kawai M, Yoshino M, Mashima Y. Fluorophotometric measurement of pH of human tears in vivo. Curr Eye Res. 1997;16(5):482-486. 8. Food and Drug Administration website. Abbreviated new drug application (ANDA): generics. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics. Updated November 16, 2016. Accessed February 23, 2017. 

Olopatadine is licensed from Kyowa Hakko Kirin Co., Ltd. Japan

PAZEO is a registered trademark of Novartis AG.

Additional Novartis Information

Medical Information

6/17 T-PAL-1342459

Use of website is governed by the Terms of Use and Privacy Policy.

© 2017 Novartis Pharmaceuticals Corporation. All rights reserved.